.

Scalar Bioscience develops products and technologies that improve the quality of life for patients and efficiency of healthcare access and delivery.

Founded in 2001 as Sensory Arts & Science, the company has successfully commercialized offerings in the hearing care market, and we have several promising technologies in vision and hearing science as well as telehealth and communications.

In 2016 we changed the company name to Scalar Bioscience to reflect the broadening of our efforts and portfolio of companies and technologies into areas beyond diagnostics to include therapeutics.

Our prevention and early intervention approach helps ensure better patient outcomes, reduced incidence, and efficiency in care delivery.

Our principal objective is to develop:

  • Products and tools for managing the occurrence, severity, and duration of certain targeted health and wellness issues;
  • In conjunction with healthcare experts and opinion leaders, and peer reviewed by key industry participants;
  • Whose value proposition involves early intervention, thereby reducing incidence and cost, and improving outcomes and efficiency in patient care delivery.

We strive to create technologies and products that address important and unmet needs in diseases and conditions that affect broad population segments, thereby creating sustainable value for our stakeholders and partners.

Our Business Model

Our business model can be generally described as an innovation-to-commercialization process. Diagnostic and therapeutic products and technologies are conceived and occasionally in-licensed, followed by a process to prove the viability of the concept and then to protect the resulting Intellectual Property.

Based on the outcome of this proof of concept phase, we will build, test, and commercialize a product or technology that can then be licensed to a partner with market reach, or we will construct and launch a new company specifically to bring the new product or technology to market.

Our innovation model is simple and elegant, and a proven way to create sustainable value and competitive advantage.

Leadership

Dave  

Dave Davis, Managing Director

Dave is the founder of Scalar Bioscience and its predecessor Sensory Arts & Science, with more than 35 years of healthcare, corporate IT management and entrepreneurial experience. Over the last 20 years, Dave has founded and led several successful technology ventures, including companies in systems integration, healthcare technology, and Internet/new media. Throughout his career, Dave has provided management and strategic consulting services to some of America´s most prestigious companies and has been a featured speaker on topics such as technology futures and entrepreneurship. Dave earned a Bachelor´s Degree in Business Administration from Ursinus College, has completed all but his thesis for a Master’s Degree in Psychology at Harvard University, and is the holder of several issued patents.

Dave leads the organization, defining its vision and strategy, and building a team and strategic relationships that enable the Company to fulfill its plan and vision for leadership in the area of health and disease management technologies.

Scientific Advisor

Peter Febbroriello

Peter´s background is varied and fascinating. He is the founder and principal of the Research Support Group, where he provides a range of R&D services to companies large and small. His background includes significant work and achievement in mechanical, electrical, and bio-medical engineering. He has authored a number of important studies in biophysics and biochemistry, and has recently provided R&D assistance to the University of Connecticut Health Center, Knolls Atomic Power Laboratory, and General Electric. Peter holds a Bachelor´s Degree in Biology/Pre-Med from University of Connecticut.

Investor Relations

Scalar Bioscience is a privately held, self-financed company. From time to time, the company offers financial participation in products or projects that would benefit from strategic partnerships or require significant resources to successfully develop and commercialize. We prefer to work with strategic investors, whether companies or individuals.

For more information on current opportunities and participation, please contact Dave Davis, Managing Director.

.